Advanced in Primary Biliary Cholangitis

Dr. Marina Roytman

Hepatology
University Faculty Associates Inc
2335 E Kashian Ln, Suite 280, 
Fresno, CA 
Offers Telehealth
Advanced in Primary Biliary Cholangitis
University Faculty Associates Inc
2335 E Kashian Ln, Suite 280, 
Fresno, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marina Roytman is a Hepatologist in Fresno, California. Dr. Roytman is rated as an Advanced provider by MediFind in the treatment of Primary Biliary Cholangitis. Her top areas of expertise are Hepatitis, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy.

Her clinical research consists of co-authoring 47 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in CA
Hospital Affiliations
Community Regional Medical Center
Clovis Community Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

UNIVERSITY FACULTY ASSOCIATES INC
2335 E Kashian Ln, Suite 280, Fresno, CA 93701

Additional Areas of Focus

Dr. Roytman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 2 Less Clinical Trials

47 Total Publications

A Perfect MASH Comparing Resmetirom and GLP-1 Agonists for Metabolic-Associated Steatohepatitis: What Does the Current Evidence Suggest?
A Perfect MASH Comparing Resmetirom and GLP-1 Agonists for Metabolic-Associated Steatohepatitis: What Does the Current Evidence Suggest?
Journal: Journal of clinical gastroenterology
Published: April 14, 2025
Similar Doctors
Advanced in Primary Biliary Cholangitis
Dr. Radhika Kumari
Hepatology
Advanced in Primary Biliary Cholangitis
Dr. Radhika Kumari
Hepatology

Community Regional Medical Center

2823 Fresno St, 
Fresno, CA 
 (0.1 miles away)
559-459-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Radhika Kumari is a Hepatologist in Fresno, California. Dr. Kumari is rated as a Distinguished provider by MediFind in the treatment of Primary Biliary Cholangitis. Her top areas of expertise are Banti's Syndrome, Fibrolamellar Carcinoma, Hepatitis, Liver Transplant, and Endoscopy. Dr. Kumari is currently accepting new patients.

Experienced in Primary Biliary Cholangitis
Dr. Mandeep Singh
Hepatology
Experienced in Primary Biliary Cholangitis
Dr. Mandeep Singh
Hepatology

Community Foundation Medical Group

7055 N Maple Ave, Suite 106, 
Fresno, CA 
 (6.9 miles away)
559-297-2259
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mandeep Singh is a Hepatologist in Fresno, California. Dr. Singh is rated as an Advanced provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Visceromegaly, Enlarged Liver, Portal Hypertension, Endoscopy, and Colonoscopy.

Experienced in Primary Biliary Cholangitis
Dr. Alvin Au
Hepatology
Experienced in Primary Biliary Cholangitis
Dr. Alvin Au
Hepatology

Advanced Digestive Medical Center Corp

1360 Bailey St, 
Hanford, CA 
 (29.5 miles away)
559-584-6499
Languages Spoken:
English
See accepted insurances

Alvin Au is a Hepatologist in Hanford, California. Dr. Au is rated as a Distinguished provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Visceromegaly, Hepatitis C, Hepatitis, Colonoscopy, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Roytman's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 10 Advanced Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile